[DXR] Daxor Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 8.65 Change: 0.15 (1.76%)
Ext. hours: Change: 0 (0%)

chart DXR

Refresh chart

Description: Daxor Corporation, a medical device manufacturing company, offers biotech services in the United States. The company develops and markets BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients with heart failure, kidney failure, hypertension, and syncope; aid in fluid and blood transfusion management in the critical care unit; and aid in the diagnosis and treatment of disorders of red blood cell volume, including polycythemia and anemia, as well as used in pre-surgical evaluation of red blood cell volume. The company also provides cryobanking services, including blood and semen storage and related services. Daxor Corporation markets its products to hospitals and radiology imaging centers. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y-1216.53% Sales Growth - 4 Quarters -1.86% Sales Growth - Q/Q8.5% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-8.38% ROE-19.84% ROI
Current Ratio1.66 Quick Ratio1.65 Long Term Debt/Equity Debt Ratio1.36
Gross Margin54.91% Operating Margin-400.21% Net Profit Margin-496.96% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities300 K Cash From Investing Activities Cash From Operating Activities-300 K Gross Profit550 K
Net Profit-500 K Operating Profit470 K Total Assets46.05 M Total Current Assets
Total Current Liabilities Total Debt Total Liabilities21.47 M Total Revenue840 K
Technical Data
High 52 week19.52 Low 52 week5.81 Last close9.46 Last change-1.46%
RSI54.11 Average true range0.22 Beta0.12 Volume1.34 K
Simple moving average 20 days0.58% Simple moving average 50 days-0.3% Simple moving average 200 days-8.38%
Performance Data
Performance Week-1.46% Performance Month1.48% Performance Quart7.53% Performance Half18.25%
Performance Year47.81% Performance Year-to-date15.37% Volatility daily2.58% Volatility weekly5.77%
Volatility monthly11.83% Volatility yearly40.98% Relative Volume69.25% Average Volume2.77 K
New High New Low

News

2020-05-29 15:34:34 | Is Daxor Corporation DXR A Good Stock To Buy According To Hedge Funds?

2020-05-26 16:50:10 | Daxor Corporation, CEO Michael Feldschuh to Participate in Maxim Group’s COVID-19 Virtual Conference on May 27, 2020

2020-05-22 08:00:10 | Daxor’s BVA-100® Published in Novel Study in American Heart Association Journal - Circulation

2020-04-23 08:30:10 | Daxor Awarded $1.1 Million Contract from United States Department of Defense DOD for Rapid Portable Blood Volume Analyzer

2020-03-20 08:00:10 | Daxor Corporation’s BVA-100® Test Used to Guide Treatment In COVID-19 Patient

2020-03-09 08:30:10 | Daxor Corporation Contracted to Adapt Its Blood Volume Analyzer Technology for U.S. Air Force Needs

2020-03-06 08:00:10 | Daxor Corporation Announces Closing of $2.0 Million Registered Direct Offering Priced At-The-Market

2020-03-04 09:48:37 | 3 Biotech Stocks Join the Coronavirus Fight

2020-03-03 09:23:49 | Daxor Corporation Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market

2020-03-02 08:00:10 | Daxor Corporation Announces Engagement with Hospitals and Government for Use of the Blood Volume Analyzer BVA-100® to Stem COVID-19 Deaths

2020-03-02 07:55:10 | DAXOR CORPORATION ANNOUNCES RISE IN KIT SALES AND FILES FORM N-CSR FOR 2019

2020-02-20 08:30:10 | New Research Further Demonstrates Clinical Superiority of Daxor Corporation’s Blood Volume Analyzer BVA-100® in Critical Care

2020-02-12 08:00:10 | Daxor Corporation to Exhibit at the Society for Critical Care Medicine 49th Congress

2019-12-31 11:20:16 | Here's What We Think About Daxor Corporation's NYSEMKT:DXR CEO Pay

2019-11-21 08:00:00 | Novel Study from Yale University Utilizes Daxor’s Blood Volume Analyzer BVA-100® to Uncover Important Mechanism for Drug Empagliflozin

2019-11-12 08:00:00 | Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2019

2019-10-29 07:37:48 | Read This Before Judging Daxor Corporation's NYSEMKT:DXR ROE

2019-10-15 08:00:00 | MicroCap Rodeo Investor Conference Lineup for October 15 and 16 - 2019

2019-10-10 08:30:00 | Daxor to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 1:30 PM Central Time

2019-09-24 08:00:00 | Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume BVA-100 Diagnostic in the Assessment of Hypertension

2019-09-19 10:15:00 | MicroCap Rodeo Investor Conference - October 15 and 16, 2019, Austin Texas

2019-09-18 08:00:00 | New Data Presented on Blood Volume at Annual Heart Failure Society Meeting Amid Call to Broadly Adopt Daxor’s Diagnostic Technology

2019-09-11 08:00:00 | Daxor Corporation to Exhibit at the 23rd Annual Scientific Meeting of the Heart Failure Society of America

2019-09-04 08:00:00 | Daxor Corporation Announces a 38 Percent Rise in BVA-100 Cardiology Kit Sales and Net Gain of $498,111 for Six Months in Filing of Form N-CSR for June 30, 2019

2019-08-30 08:59:56 | How Do Daxor Corporation’s NYSEMKT:DXR Returns Compare To Its Industry?

2019-08-06 08:00:00 | Daxor Corporation Announces the Acquisition of the BVA-100® Blood Volume Analyzer by a Leading Academic Health Center in the Pacific Northwest

2019-06-18 08:00:00 | Daxor Corporation Announces New Research Initiative with Leading Hospital in the Southeast and the BVA-100® Blood Volume Diagnostic Test

2019-05-31 08:00:00 | Daxor Corporation to Present at the LD Micro 9th Annual Invitational on June 4th, 2019

2019-05-30 08:00:00 | Daxor Corporation Announces New Partnership with Leading Hospital in North Carolina to Integrate the BVA-100® Blood Volume Analyzer Diagnostic Test as Part of Standard Clinical Practice

2019-05-27 11:28:28 | Our Take On Daxor Corporation's NYSEMKT:DXR CEO Salary

2019-03-21 08:30:00 | Daxor Corporation Addresses and Corrects Erroneous Seeking Alpha Healthcare News Editor Article of March 20, 2019

2019-03-15 08:30:00 | Daxor Corporation to Present at the 31st Annual Roth Conference on March 19, 2019

2019-03-04 08:30:00 | Daxor Corporation Announces Rise in Kit Sales and Files Form N-CSR For 2018

2019-02-22 08:37:51 | New Research Further Demonstrates Clinical Utility and Improved Ease of Use with Daxor Corporation’s Blood Volume Analyzer BVA-100® in Critical Care

2019-02-13 08:30:00 | Daxor Corporation to Exhibit at the Society for Critical Care Medicine 48th Congress

2019-01-23 08:30:00 | Daxor Corporation Appoints Guido Manzo, Vice President of Sales

2019-01-10 08:30:00 | Daxor Corporation Announces Acquisition of BVA-100® Blood Volume Analyzer to Aspirus Wausau Hospital in Wisconsin

2018-11-13 08:30:00 | New Data Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer BVA-100 in Evaluation of Hypertension

2018-11-08 13:46:45 | New Data Demonstrating the Clinical Utility of Daxor’s BVA-100 in Hypertension Management to be Presented at the American Heart Association’s Scientific Sessions 2018 

2018-11-07 08:30:00 | Daxor Corporation Selected for U.S. Army Contract to Develop a Blood Volume Analyzer for Improvement of Combat Casualty Care

2018-11-01 08:30:00 | CHF Solutions Initiates Strategic Collaboration with Daxor Corporation to Assist in the Management of Patients with Fluid Overload

2018-11-01 08:30:00 | Daxor Corporation Initiates Strategic Collaboration with CHF Solutions, Inc. to Manage Patients with Fluid Overload

2018-10-30 08:30:00 | New Study Cites 82 Percent Mortality and 56 Percent Rehospitalization Reductions 30 Days After Therapy Guided by Daxor’s BVA-100 Blood Volume Analyzer in Acute Heart Failure Patients

2018-09-28 08:30:00 | Daxor Corporation Appoints Robert J. Michel as Chief Financial Officer

2018-09-25 08:30:00 | Daxor Corporation to Present at The MicroCap Conference on October 2, 2018

2018-09-17 08:30:00 | New Independent Data Further Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer BVA-100 Over Surrogate Measurements

2018-09-12 08:30:00 | Daxor Corporation to Exhibit at the 22nd Annual Scientific Meeting of the Heart Failure Society of America

2018-08-24 08:30:00 | Daxor Corporation Announces a 23 Percent Rise in BVA-100 Kit Sales in the Area of Cardiology and Filing of Form N-CSR for June 30, 2018

2018-08-20 08:30:00 | Newly Published Data Show Daxor Corporation's BVA-100 Is Superior To Formula-Based Estimates of Blood Volume In Assessing Patients With Heart Failure

2018-08-02 08:00:00 | Today’s Research Reports on Stocks to Watch: RXi Pharmaceuticals and Neurocrine Biosciences